Pradaxa is an anticoagulant used to reduce the risk of stroke and prevent as well as treat the formation of blood clots (conditions such as deep vein thrombosis, pulmonary embolism, systemic thromboembolism, etc.) in patients suffering from atrial fibrillation as well as patients who have undergone a hip replacement surgery. This medicine is not recommended for use in patients less than 18 years of age.
Pradaxa from Boehringer contains Dabigatran. Dabigatran etexilate is prescribed for the prevention of thrombotic events in patients who underwent hip or knee replacement surgery. Dabigatran etexilate is used for the prevention of stroke in atrial fibrillation patients with other risks such as diabetes, hypertension, CHF, age and clinical history of stroke.
Pradaxa is product of Boehringer Ingelheim. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world’s largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company’s key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system.